Semin Liver Dis 2013; 33(S 01): S11-S19
DOI: 10.1055/s-0033-1333632
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Emerging Targeted Strategies in Advanced Hepatocellular Carcinoma

Richard S. Finn
1   Division of Hematology/Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California
› Author Affiliations
Further Information

Publication History

Publication Date:
01 March 2013 (online)

Abstract

Treatment of advanced-stage hepatocellular carcinoma (HCC) remains a challenge because of the complex nature of the disease and the lack of available therapies. The antiangiogenic multikinase inhibitor sorafenib is the first therapy to demonstrate a significant overall survival benefit in advanced HCC. However, new agents for both first- and second-line treatment of advanced HCC are needed. The multiple pathways involved in HCC oncogenesis, proliferation, and survival provide many opportunities for the development of molecularly targeted therapies. Many novel agents are under investigation in phase III trials in advanced HCC, including antiangiogenic multikinase inhibitors (e.g., brivanib, sunitinib, linifanib) and inhibitors of the mammalian target of rapamycin (mTOR) pathway (e.g., everolimus). Although these therapies have demonstrated some utility as single agents in advanced HCC, rational combinations of therapies are likely to provide greater success. Current research efforts are directed at combining agents targeting different molecular pathways (e.g., sorafenib in combination with erlotinib) and combining molecularly targeted agents with systemic chemotherapy or transarterial chemoembolization (TACE). Therapies targeting other molecular pathways in HCC are in early development; future research will focus on discovering additional targets for therapy and identifying biomarkers that predict the success of current therapies.

 
  • References

  • 1 Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis 2009; 27 (2) 80-92
  • 2 Imamura H, Matsuyama Y, Tanaka E , et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38 (2) 200-207
  • 3 Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991; 14 (5) 802-805
  • 4 Poon RT, Fan ST, Lo CM, Liu C-L, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999; 229 (2) 216-222
  • 5 Llovet JM, Bruix J. for the Barcelona-Clinic Liver Cancer Group. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (2) 429-442
  • 6 Marin JJG, Castaño B, Martinez-Becerra P, Rosales R, Monte MJ. Chemotherapy in the treatment of primary liver tumours. Cancer Ther 2008; 6: 711-728
  • 7 Llovet JM, Ricci S, Mazzaferro V , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4) 378-390
  • 8 Cheng AL, Kang YK, Chen Z , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1) 25-34
  • 9 Sanz-Cameno P, Trapero-Marugán M, Chaparro M, Jones EA, Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010; 2010: 272170
  • 10 Semela D, Dufour J-F. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41 (5) 864-880
  • 11 Park YN, Kim Y-B, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124 (7) 1061-1065
  • 12 Poon RT, Ng I-O, Lau C , et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233 (2) 227-235
  • 13 Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007; 14 (6) 1835-1845
  • 14 Mas VR, Maluf DG, Archer KJ, Yanek KC, Fisher RA. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 2007; 84 (10) 1262-1271
  • 15 Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91 (10) 1354-1360
  • 16 Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004; 11 (5) 1077-1084
  • 17 Hsu PI, Chow NH, Lai KH , et al. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res 1997; 17 (4A) 2803-2809
  • 18 Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 115-165
  • 19 Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16 (2) 159-178
  • 20 Uematsu S, Higashi T, Nouso K , et al. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20 (4) 583-588
  • 21 Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001; 182 (3) 298-304
  • 22 Yoshiji H, Kuriyama S, Yoshii J , et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002; 35 (4) 834-842
  • 23 Huang X, Yu C, Jin C , et al. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res 2006; 66 (3) 1481-1490
  • 24 Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8 (8) 592-603
  • 25 Sawey ET, Chanrion M, Cai C , et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011; 19 (3) 347-358
  • 26 Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis 2011; 29 (3) 289-302
  • 27 Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4 (5) 335-348
  • 28 Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 2009; 9 (2) 247-261
  • 29 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 14: 1312-1327
  • 30 Villanueva A, Chiang DY, Newell P , et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135 (6) 1972-1983 , e1–e11
  • 31 Schmitz KJ, Wohlschlaeger J, Lang H , et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008; 48 (1) 83-90
  • 32 Abou-Alfa GK, Schwartz L, Ricci S , et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26) 4293-4300
  • 33 Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?. Clin Cancer Res 2010; 16 (2) 390-397
  • 34 Boyault S, Rickman DS, de Reyniès A , et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45 (1) 42-52
  • 35 Rimassa L, Porta C, Borbath I , et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT). J Clin Oncol 2012; 30 (Suppl): Abstract 4006
  • 36 Ito Y, Takeda T, Sakon M , et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84 (10) 1377-1383
  • 37 Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 2011; 4: 30-41
  • 38 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115 (24) 5651-5661
  • 39 Siegel AB, Olsen SK, Magun A, Brown Jr RS. Sorafenib: where do we go from here?. Hepatology 2010; 52 (1) 360-369
  • 40 Zhu AX, Sahani DV, Duda DG , et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27 (18) 3027-3035
  • 41 Cheng A, Kang Y, Lin D , et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011; 29 (suppl): Abstract 4000
  • 42 Park JW, Finn RS, Kim JS , et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17 (7) 1973-1983
  • 43 Llovet JM, Decaens T, Raoul J-L , et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. Abstract presented at: 47th Annual Meeting of the European Association for the Study of the Liver; April 18–22, 2012; Barcelona, Spain
  • 44 Toh H-C, Chen P-J, Carr BI , et al. Linifanib in advanced hepatocellular carcinoma (HCC): a phase 2 trial. Hepatology 2010; 52 (Suppl. 01) Abstract 1777
  • 45 Philip PA, Mahoney MR, Allmer C , et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23 (27) 6657-6663
  • 46 Thomas MB, Chadha R, Glover K , et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110 (5) 1059-1067
  • 47 Zhu AX, Rosmorduc O, Evans J , et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol 2012; 23 (Suppl. 09) Abstract LBA2
  • 48 Siegel AB, Cohen EI, Ocean A , et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26 (18) 2992-2998
  • 49 Zhu AX, Finn RS, Mulcahy MF , et al. A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma. J Clin Oncol 2010; 28 (15S) Abstract 4083
  • 50 Zhu AX, Abrams TA, Miksad R , et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011; 117 (22) 5094-5102
  • 51 Glazer ES, Piccirillo M, Albino V , et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010; 28 (13) 2220-2226
  • 52 Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). Available at: http://clinicaltrials.gov/ct2/show/NCT01015833 . Accessed January 11, 2012
  • 53 Sorafenib in the first-line treatment of advanced hepatocellular carcinoma with Child-Pugh liver function class B: multicentre phase 3 randomized trial. Available at: http://clinicaltrials.gov/cts/show/NCT01405573 . Accessed January 11, 2012
  • 54 An open-label, randomized phase 3 study of the efficacy and tolerability of linifanib (ABT-869) versus sorafenib in subjects with advanced hepatocellular carcinoma (HCC). Available at: http://clinicaltrials.gov/ct2/show/NCT01009593 . Accessed January 11, 2012
  • 55 A randomized, double-blind multicenter phase III study of brivanib versus sorafenib as first-line treatment in patients with hepatocellular carcinoma (BRISK-FL). Available at: http://clinicaltrials.gov/ct2/show/NCT00858871 . Accessed January 11, 2012
  • 56 BRISK-FL study with investigational compound brivanib in hepatocellular carcinoma does not meet overall survival primary endpoint [press release]. Princeton, NJ: Bristol-Myers Squibb; July 19, 2012. Available at: http://www.reuters.com/article/2012/07/19/idUS218420+19-Jul-2012+BW20120719 . Accessed July 20, 2012
  • 57 A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to sorafenib (BRISK-APS). Available at: http://clinicaltrials.gov/ct2/show/NCT01108705 . Accessed January 11, 2012
  • 58 A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced hepatocellular carcinoma after failure of sorafenib treatment–The EVOLVE-1 Study. Available at: http://clinicaltrials.gov/ct2/show/NCT01035229 . Accessed January 11, 2012
  • 59 A multicenter, randomized, double-blind, phase 3 study of ramucirumab (IMC-1121B) drug product and best supportive care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma following first-line therapy with sorafenib (REACH). Available at: http://clinicaltrials.gov/ct2/show/NCT01140347 . Accessed January 11, 2012
  • 60 A DI-PEG 20 versus placebo in subjects with advanced hepatocellular carcinoma who have failed prior systemic therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT01287585 . Accessed September 25, 2012
  • 61 A phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation. Available at: http://clinicaltrials.gov/ct2/show/NCT00692770 . Accessed February 23, 2012
  • 62 A phase III randomized, double-blind trial of chemoembolization with or without sorafenib in unresectable hepatocellular carcinoma (HCC) in patients with and without vascular invasion. Available at: http://clinicaltrials.gov/ct2/show/NCT01004978 . Accessed February 23, 2012
  • 63 TACE-2. A randomized placebo-controlled, double blinded, phase III trial of sorafenib in combination with transarterial chemoembolization in hepatocellular cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01324076 . Accessed February 23, 2012
  • 64 A randomized, double-blind, multicenter phase III study of brivanib versus placebo as adjuvant therapy to trans-arterial chemo-embolization (TACE) in patients with unresectable hepatocellular carcinoma (The BRISK TA Study). Available at: http://clinicaltrials.gov/ct2/show/NCT00908752 . Accessed January 11, 2012
  • 65 Orantinib in combination with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma (ORIENTAL). Available at: http://clinicaltrials.gov/ct2/show/NCT01465464 . Accessed September 25, 2012
  • 66 Faivre S, Raymond E, Boucher E , et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10 (8) 794-800
  • 67 Huynh H, Ngo VC, Fargnoli J , et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14 (19) 6146-6153
  • 68 Finn RS, Kang YK, Mulcahy M , et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18 (7) 2090-2098
  • 69 Albert DH, Tapang P, Magoc TJ , et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006; 5 (4) 995-1006
  • 70 Blaszkowsky L, Abrams T, Miksad R , et al. Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma. J Clin Oncol 2010; 28 (Suppl): Abstract e14542
  • 71 Thomas MB, Morris JS, Chadha R , et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27 (6) 843-850
  • 72 Finn RS, Poon TP, Yau T , et al. Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011; 29 (Suppl): Abstract 4074
  • 73 Abou-Alfa GK, Johnson P, Knox JJ , et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304 (19) 2154-2160
  • 74 Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). Available at: http://clinicaltrials.gov/ct2/show/NCT01015833 . Accessed January 11, 2012
  • 75 Hsu C-H, Yang T-S, Hsu C , et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 102 (6) 981-986
  • 76 Sun W, Sohal D, Haller DG , et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011; 117 (14) 3187-3192
  • 77 Zhu AX, Blaszkowsky LS, Ryan DP , et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (12) 1898-1903
  • 78 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407 (6801) 249-257
  • 79 Li X, Feng G-S, Zheng C-S, Zhuo C-K, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10 (19) 2878-2882
  • 80 Sergio A, Cristofori C, Cardin R , et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103 (4) 914-921
  • 81 Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29 (30) 3960-3967
  • 82 Lencioni R, Zou JM, Leberre M , et al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma: Phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012; 30 (Suppl. 04) Abstract LBA154
  • 83 Okita K, Imanaka K, Chida N , et al. Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma (HCC) treated after transarterial chemoembolization (TACE). Abstract presented at the 2010 Gastrointestinal Cancers Symposium; January 22–24, 2010; Orlando, FL